Acelyrin, Inc. (Nasdaq: SLRN), a pharmaceutical company dedicated to developing innovative therapies, caught the attention of Jefferies, which initiated coverage on the stock with a Buy rating and a price target of $31. 

Despite $SLRN closing at $18.17 on Tuesday with a decline of $1.10 or 5.71%, this initiation suggests a potential upside of $12.83 or 70.67% based on Jefferies' price target.

CRISPR Therapeutics AG (Nasdaq: CRSP), a leading biotechnology company specializing in gene-editing technology, received coverage initiation from William Blair with an Outperform rating and a price target of $75. 

While $CRSP closing at $64.63 on Tuesday with a marginal decrease of $0.03 or 0.05%, the initiation implies a potential upside of $10.37 or 16.04% according to William Blair's price target.

Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical-stage biopharmaceutical company focusing on precision medicine in oncology, received an upgrade from SVB Securities, transitioning from Market Perform to Outperform. Additionally, the price target was raised from $5 to $8. 

Despite $ELEV closing at $4.35 on Tuesday, experiencing a decline of $0.67 or 13.35%, this upgrade suggests a potential upside of $3.65 or 83.91% based on SVB Securities' revised price target.

STERIS plc (NYSE: STE), a leading provider of infection prevention and surgical products, received coverage initiation from Morgan Stanley with an Equal-Weight rating and a price target of $206. 

Although $STE closing at $199.55 on Tuesday with a slight decrease of $0.89 or 0.44%, this initiation indicates a potential upside of $6.45 or 3.24% based on Morgan Stanley's price target.

Teleflex Incorporated (NYSE: TFX), a global medical device company, attracted the attention of CL King, which initiated coverage on the stock with a Buy rating and a price target of $293. 

Despite $TFX closing at $232.06 on Tuesday with a minimal decline of $0.29 or 0.12%, this initiation implies a potential upside of $60.94 or 26.29% according to CL King's price target.

Please note that the assessments and price targets mentioned above are based on the opinions and analyses of the respective firms and analysts referenced. It is important for investors to conduct their own thorough research and take into account various factors before making any investment decisions.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)